Intravenous cell therapies for stroke

Osman Mir, Aditya P. Lal, Farhaan S. Vahidy, Kaushik Parsha, Sean I. Savitz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Stroke is the leading cause of disability and there are no proven therapies beyond the acute stage. Based on extensive animal data, there is mounting evidence that various types of cell therapies enhance recovery after stroke. We review intravenous delivery of cell therapies in animal studies and clinical trials. The intravenous delivery of various cell types has been reported to activate several different signaling mechanisms such as neuroprotective, immunomodulatory, and repair-enhancing processes in the brain. It has also been shown that although peripherally injected stem cells get trapped in the pulmonary circulation, they secrete paracrine factors and exert a profound effect on neural recovery in animal models. MSCs are also thought to interact within the reticuloendothelial system by inducing or inhibiting migration of different immune cells. This chapter also identifies major issues that need to be addressed going forward including optimal cell types of cells, patient populations, and time windows.

Original languageEnglish (US)
Title of host publicationCell-Based Therapies in Stroke
PublisherSpringer-Verlag Wien
Pages171-179
Number of pages9
ISBN (Electronic)9783709111758
ISBN (Print)9783709111741
DOIs
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Intravenous cell therapies for stroke'. Together they form a unique fingerprint.

Cite this